Multicenter, Dose-Finding Safety and Activity Study of AMD11070 in HIV-Infected Patients Carrying X4-Tropic Virus.
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Mavorixafor (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms XACT
- Sponsors AnorMED; Genzyme Corporation
- 08 Sep 2010 Actual end date (October 2005) added as reported by ClinicalTrials.gov.
- 08 Sep 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
- 28 Jul 2009 Actual patient number (9) added as reported by ClinicalTrials.gov.